Glycosylated polypeptide and pharmaceutical composition containing same
AssigneeGlytech, Inc.
InventorsIzumi Sakamoto, Kazuhiro Fukae, Katsunari Tezuka, Keisuke Tazuru, Masatoshi Maeda, Yasuhiro Kajihara, Takashi Tsuji
Life of this patent
Estimating the term…
Abstract
The object of the present invention is to provide a glycosylated polypeptide having uniform sugar chain structure which has interferon β activity. It was found that a glycosylated polypeptide having uniform sugar chain structure as well as having interferon β activity can be prepared by a method comprising a step of synthesizing a glycosylated peptide fragment and at least two peptide fragments and a step of linking the glycosylated peptide fragment and the at least two peptide fragments.
Claims27
A glycosylated polypeptide chain characterized in that said glycosylated polypeptide is a polypeptide selected from the group consisting of:
- (a) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1;
- (b) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1 having one or a few amino acids deleted, substituted, or added;
- (c) an interferon β analog;
- and
- (d) a polypeptide having 80% or more homology with a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1;
- wherein the polypeptide has a sugar chain at the amino acid corresponding to position 80 in interferon β and has interferon β activity, and
- said glycosylated polypeptide has substantially uniform sugar chains.
A glycosylated polypeptide obtained by a method comprising a step of synthesizing a glycosylated peptide fragment and at least two peptide fragments and a step of linking said glycosylated peptide fragment and said at least two peptide fragments, characterized in that said glycosylated polypeptide is a polypeptide selected from the group consisting of:
- (a) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1;
- (b) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1 having one or a few amino acids deleted, substituted, or added;
- (c) an interferon β analog;
- and
- (d) a polypeptide having 80% or more homology with a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1;
- wherein the polypeptide has a sugar chain at the amino acid corresponding to position 80 in interferon β and has interferon β activity.
A glycosylated polypeptide characterized in that said glycosylated polypeptide is a polypeptide selected from the group consisting of:
- (a) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1;
- (b) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1 having one or a few amino acids deleted, substituted, or added;
- (c) an interferon β analog;
- and
- (d) a polypeptide having 80% or more homology with a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1;
- wherein the polypeptide has a sugar chain at the amino acid corresponding to position 80 in interferon β and has Cys corresponding to positions 17, 31, and 141 in interferon β protected by a protecting group.
A glycosylated polypeptide, characterized in that said glycosylated polypeptide is a polypeptide selected from the group consisting of:
- (a) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1;
- (b) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1 having one or a few amino acids deleted, substituted, or added;
- (c) an interferon β analog;
- and
- (d) a glycosylated polypeptide having 80% or more homology with a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1;
- wherein the polypeptide has a sugar chain at the amino acid corresponding to position 80 in interferon β, and
- said sugar chain is a disialo sugar chain having the carboxy group of the sialic acid present at the sugar chain non-reducing terminal protected represented by the following formula (c),
- (wherein R represents —COOBn, —COOEt, —COOMe, —COOCH2COPh, —COOCH2PhOMe, —COOCH2Ph(OMe)2, —COOCH2PhNO2, or —COOCH2Ph(NO2)2. Bn indicates a benzyl group, Et indicates an ethyl group, Me indicates a methyl group, and Ph indicates a phenyl group).
Dependencies are inferred from the claim text.